[go: up one dir, main page]

WO2005055950A3 - Glycopegylated factor ix - Google Patents

Glycopegylated factor ix Download PDF

Info

Publication number
WO2005055950A3
WO2005055950A3 PCT/US2004/041070 US2004041070W WO2005055950A3 WO 2005055950 A3 WO2005055950 A3 WO 2005055950A3 US 2004041070 W US2004041070 W US 2004041070W WO 2005055950 A3 WO2005055950 A3 WO 2005055950A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
peptide
methods
glycosyltransferase
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/041070
Other languages
French (fr)
Other versions
WO2005055950A2 (en
Inventor
Shawn Defrees
Robert J Bayer
Caryn Bowe
Krishnasamy Panneerselvam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neose Technologies Inc
Original Assignee
Neose Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2004800359517A priority Critical patent/CN1889937B/en
Priority to EP04813394A priority patent/EP1694315A4/en
Priority to CA002549413A priority patent/CA2549413A1/en
Priority to BRPI0417341-4A priority patent/BRPI0417341A/en
Priority to MXPA06006023A priority patent/MXPA06006023A/en
Priority to AU2004296860A priority patent/AU2004296860B2/en
Priority to JP2006542888A priority patent/JP4738346B2/en
Priority to NZ546733A priority patent/NZ546733A/en
Application filed by Neose Technologies Inc filed Critical Neose Technologies Inc
Publication of WO2005055950A2 publication Critical patent/WO2005055950A2/en
Priority to US11/166,028 priority patent/US20060040856A1/en
Publication of WO2005055950A3 publication Critical patent/WO2005055950A3/en
Priority to IL175661A priority patent/IL175661A0/en
Priority to KR1020067010603A priority patent/KR101209111B1/en
Anticipated expiration legal-status Critical
Priority to US12/184,956 priority patent/US20090081188A1/en
Priority to US12/851,651 priority patent/US8632770B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides conjugates between Factor IX and PEG moieties. The conjugates are linked via an intact glycosyl linking group interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from glycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto a glycosyl residue on the peptide. Also provided are methods for preparing the conjugates, methods for treating various disease conditions with the conjugates, and pharmaceutical formulations including the conjugates.
PCT/US2004/041070 2003-12-03 2004-12-03 Glycopegylated factor ix Ceased WO2005055950A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
NZ546733A NZ546733A (en) 2003-12-03 2004-12-03 Glycopegylated factor IX
EP04813394A EP1694315A4 (en) 2003-12-03 2004-12-03 GLYCOPEGYLATED FACTOR IX
CA002549413A CA2549413A1 (en) 2003-12-03 2004-12-03 Glycopegylated factor ix
BRPI0417341-4A BRPI0417341A (en) 2003-12-03 2004-12-03 glyceguiled factor ix
MXPA06006023A MXPA06006023A (en) 2003-12-03 2004-12-03 Glycopegylated factor ix.
AU2004296860A AU2004296860B2 (en) 2003-12-03 2004-12-03 Glycopegylated factor IX
JP2006542888A JP4738346B2 (en) 2003-12-03 2004-12-03 GlycoPEGylated factor IX
CN2004800359517A CN1889937B (en) 2003-12-03 2004-12-03 Glycopegylated Factor IX Peptide
US11/166,028 US20060040856A1 (en) 2003-12-03 2005-06-23 Glycopegylated factor IX
IL175661A IL175661A0 (en) 2003-12-03 2006-05-16 Glycopegylated factor ix
KR1020067010603A KR101209111B1 (en) 2003-12-03 2006-05-30 Glycopezylation Factor Nine
US12/184,956 US20090081188A1 (en) 2003-12-03 2008-08-01 Glycopegylated factor ix
US12/851,651 US8632770B2 (en) 2003-12-03 2010-08-06 Glycopegylated factor IX

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US52708903P 2003-12-03 2003-12-03
US60/527,089 2003-12-03
US53938704P 2004-01-26 2004-01-26
US60/539,387 2004-01-26
US59274404P 2004-07-29 2004-07-29
US60/592,744 2004-07-29
US61451804P 2004-09-29 2004-09-29
US60/614,518 2004-09-29
US62338704P 2004-10-29 2004-10-29
US60/623,387 2004-10-29

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/166,028 Continuation-In-Part US20060040856A1 (en) 2003-12-03 2005-06-23 Glycopegylated factor IX

Publications (2)

Publication Number Publication Date
WO2005055950A2 WO2005055950A2 (en) 2005-06-23
WO2005055950A3 true WO2005055950A3 (en) 2005-10-20

Family

ID=34682416

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/041070 Ceased WO2005055950A2 (en) 2003-12-03 2004-12-03 Glycopegylated factor ix

Country Status (10)

Country Link
EP (1) EP1694315A4 (en)
JP (1) JP4738346B2 (en)
KR (1) KR101209111B1 (en)
AU (1) AU2004296860B2 (en)
BR (1) BRPI0417341A (en)
CA (1) CA2549413A1 (en)
IL (1) IL175661A0 (en)
MX (1) MXPA06006023A (en)
NZ (1) NZ546733A (en)
WO (1) WO2005055950A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076292B2 (en) 2001-10-10 2011-12-13 Novo Nordisk A/S Factor VIII: remodeling and glycoconjugation of factor VIII
US8404809B2 (en) 2005-05-25 2013-03-26 Novo Nordisk A/S Glycopegylated factor IX
US8632770B2 (en) 2003-12-03 2014-01-21 Novo Nordisk A/S Glycopegylated factor IX
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
AU2004221824B2 (en) 2003-03-14 2009-08-27 Ratiopharm Gmbh Branched water-soluble polymers and their conjugates
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US8361961B2 (en) 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
AU2014280936B2 (en) * 2004-06-30 2016-12-15 Nektar Therapeutics Polymer-factor ix moiety conjugates
ES2390082T5 (en) * 2004-06-30 2018-01-19 Nektar Therapeutics Factor IX remainder conjugates and polymers
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
JP5948627B2 (en) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー Fibroblast growth factor (FGF) remodeling and carbohydrate pegylation
ES2449195T3 (en) 2005-01-10 2014-03-18 Ratiopharm Gmbh Glycopegylated granulocyte colony stimulating factor
US20070154992A1 (en) 2005-04-08 2007-07-05 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
BRPI0614839A2 (en) * 2005-08-19 2009-05-19 Neose Technologies Inc glycopeguiled factor vii and factor viia
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
JP2009544327A (en) * 2006-07-21 2009-12-17 ノヴォ ノルディスク アー／エス Glycosylation of peptides with O-linked glycosylation sequences
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
JP5457185B2 (en) * 2006-10-04 2014-04-02 ノヴォ ノルディスク アー／エス Glycerol-linked PEGylated sugars and glycopeptides
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
JP2010523582A (en) 2007-04-03 2010-07-15 バイオジェネリクス アクチェンゲゼルシャフト Treatment method using glycoPEGylated G-CSF
EP2517714A1 (en) * 2007-04-26 2012-10-31 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
WO2009051717A2 (en) * 2007-10-15 2009-04-23 The University Of North Carolina At Chapel Hill Human factor ix variants with an extended half life
CN101952422A (en) * 2007-12-27 2011-01-19 巴克斯特国际公司 The factors IX of chemically modified
JP5619630B2 (en) 2008-02-27 2014-11-05 ノボ・ノルデイスク・エー／エス Binding factor VIII molecule
CN102083856A (en) * 2008-04-16 2011-06-01 拜耳医药保健有限公司 Modified factor IX polypeptides and uses thereof
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
RU2744370C2 (en) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
WO2011017055A2 (en) 2009-07-27 2011-02-10 Baxter International Inc. Blood coagulation protein conjugates
NZ597600A (en) 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
KR20120060209A (en) * 2009-07-31 2012-06-11 바이엘 헬스케어 엘엘씨 Modified factor ix polypeptides and uses thereof
WO2011064247A1 (en) 2009-11-24 2011-06-03 Novo Nordisk Health Care Ag Method of purifying pegylated proteins
KR20220097518A (en) 2010-07-09 2022-07-07 바이오버라티브 테라퓨틱스 인크. Factor ix polypeptides and methods of use thereof
JP6138052B2 (en) 2010-12-22 2017-05-31 バクスアルタ ゲーエムベーハー Materials and methods for conjugating water soluble fatty acid derivatives to proteins
TW201519900A (en) * 2013-04-28 2015-06-01 Bayer Healthcare Llc Compositions and methods for inducing immune tolerance to coagulation factor proteins
AU2020242945B2 (en) 2019-03-19 2025-06-26 CSL Innovation Pty Ltd Factor IX variants and uses thereof in therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440703B1 (en) * 1997-12-01 2002-08-27 Neose Technologies, Inc. Enzymatic synthesis of gangliosides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (en) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd Novel blood coagulation factor derivative, its preparation and blood coagulation promoting agent containing the same
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
SE9503380D0 (en) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
EP2305313B1 (en) * 2001-10-10 2014-03-26 ratiopharm GmbH Remodelling and glycoconjugation of interferon-alpha (IFNa)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440703B1 (en) * 1997-12-01 2002-08-27 Neose Technologies, Inc. Enzymatic synthesis of gangliosides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TUDDENHAM E. ET AL.: "RNA as drug an antidote.", NATURE, vol. 419, 5 September 2002 (2002-09-05), pages 23 - 24, XP002990010 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076292B2 (en) 2001-10-10 2011-12-13 Novo Nordisk A/S Factor VIII: remodeling and glycoconjugation of factor VIII
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US8632770B2 (en) 2003-12-03 2014-01-21 Novo Nordisk A/S Glycopegylated factor IX
US8404809B2 (en) 2005-05-25 2013-03-26 Novo Nordisk A/S Glycopegylated factor IX

Also Published As

Publication number Publication date
NZ546733A (en) 2009-07-31
JP2007513190A (en) 2007-05-24
WO2005055950A2 (en) 2005-06-23
CA2549413A1 (en) 2005-06-23
KR101209111B1 (en) 2012-12-06
AU2004296860B2 (en) 2010-04-22
EP1694315A2 (en) 2006-08-30
AU2004296860A1 (en) 2005-06-23
EP1694315A4 (en) 2009-10-28
BRPI0417341A (en) 2007-04-17
KR20060123224A (en) 2006-12-01
JP4738346B2 (en) 2011-08-03
IL175661A0 (en) 2006-09-05
MXPA06006023A (en) 2006-08-23

Similar Documents

Publication Publication Date Title
WO2005055950A3 (en) Glycopegylated factor ix
WO2005051327A3 (en) Glycopegylated erythropoietin
WO2006127896A3 (en) Glycopegylated factor ix
WO2006127910A3 (en) Glycopegylated erythropoietin formulations
WO2006031811A3 (en) Glycopegylated interferon alpha
WO2005055946A3 (en) Glycopegylated granulocyte colony stimulating factor
WO2005056760A3 (en) Glycopegylated follicle stimulating hormone
WO2006074467A3 (en) Glycopegylated granulocyte colony stimulating factor
WO2007022512A3 (en) Glycopegylated factor vii and factor viia
WO2006081249A3 (en) Conjugates of biologically active proteins having a modified in vivo half-life
WO2006020372A3 (en) Enzymatic modification of glycopeptides
YU48703A (en) New interferon beta-like molecules
WO2005029076A3 (en) Nanoparticle conjugates and method of production thereof
WO2005030259A3 (en) Nucleic acid-lipophilic conjugates
WO2005058941A3 (en) Aβ IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
WO2005030258A3 (en) Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2005058940A3 (en) Immunogenic peptide carrier conjugates and methods of producing same
WO2003055916A3 (en) Adiponectin fragments and conjugates
TW200505939A (en) Process for production of cyclic peptides
WO2002032461A3 (en) Protein c or activated protein c-like molecules
WO2001015736A3 (en) Interferon-beta conjugates
WO2001047956A3 (en) Method for obtaining proteins having improved functional characteristics
WO2001014395A3 (en) Novel glycoconjugates, glycoamino, acids, intermediates thereto, and uses thereof
WO2004044223A3 (en) Prodrugs of vancomycin with hydrolysis resistant polymer linkers
WO2001016169A3 (en) RET LIGAND 5 (Retl5) FROM HUMAN AND MOUSE

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480035951.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 11166028

Country of ref document: US

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWP Wipo information: published in national office

Ref document number: 11166028

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004296860

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 546733

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 175661

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2004296860

Country of ref document: AU

Date of ref document: 20041203

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004296860

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/006023

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020067010603

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006/04554

Country of ref document: ZA

Ref document number: 200604554

Country of ref document: ZA

Ref document number: 2549413

Country of ref document: CA

Ref document number: 2006542888

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1541/KOLNP/2006

Country of ref document: IN

REEP Request for entry into the european phase

Ref document number: 2004813394

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004813394

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004813394

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067010603

Country of ref document: KR

ENP Entry into the national phase

Ref document number: PI0417341

Country of ref document: BR